CN114350603A - Mesenchymal stem cell extracellular matrix containing exosome, preparation method thereof and application thereof in cell repair - Google Patents
Mesenchymal stem cell extracellular matrix containing exosome, preparation method thereof and application thereof in cell repair Download PDFInfo
- Publication number
- CN114350603A CN114350603A CN202210075818.4A CN202210075818A CN114350603A CN 114350603 A CN114350603 A CN 114350603A CN 202210075818 A CN202210075818 A CN 202210075818A CN 114350603 A CN114350603 A CN 114350603A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- extracellular matrix
- serum
- stem cells
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a mesenchymal stem cell conditioned medium, and preparation and application thereof, in particular to a human umbilical cord mesenchymal stem cell extracellular matrix containing exosome, and preparation and application thereof in repairing corneal epithelial cells. The preparation is culture supernatant produced by culturing human umbilical cord mesenchymal stem cells in a basal medium containing low-concentration serum under the condition of low oxygen content. The invention simulates hypoxia condition in vitro, controls serum concentration to culture mesenchymal stem cells, obtains culture supernatant showing the capability of remarkably promoting corneal epithelial cell damage repair, and has high PDGF and IV type collagen expression compared with the culture supernatant obtained under the normal oxygen condition.
Description
Technical Field
The invention relates to a mesenchymal stem cell conditioned medium, and preparation and application thereof, in particular to a human umbilical cord mesenchymal stem cell extracellular matrix containing exosome, and preparation and application thereof in repairing corneal epithelial cells.
Background
The mesenchymal stem cells can secrete various cytokines, such as immune factors (HGF, LIF), chemotactic factors (RANTES, SDF-1 alpha, fractalkine, MIP-1 alpha, MCP-1, MCP-2), vascular regeneration factors (VEGF165, FGF-2, PDGF-AA, PDGF, EGF), scar inhibition factors (HGF, FGF-2), various types of collagen (collagen type I, II, III, IV) and various lysozyme, and the like. These cytokines can be involved in the treatment and repair of a variety of diseases.
The corneal epithelium is a physical barrier against the invasion of external pathogenic agents, and the maintenance of its integrity depends on the intercellular, tight and anchored junctions between cells and basement membrane and the constant self-renewal of epithelial cells. The damage of the corneal epithelial layer can affect the connection between cells, cause the change of the permeability and selectivity of cell membranes, thereby affecting the barrier function of the cell membranes, and lead the cornea to be easily attacked by external pathogenic factors to cause inflammation, cause corneal opacity and even cause blindness. The clinical treatment method for corneal epithelial injury comprises the treatment by adopting autologous serum and nutrient factor eye drops, but the treatment effect is poor.
The hypoxia is widely applied to stem cell proliferation, differentiation and stress response researches, and most of the researches show that the hypoxia does not influence the phenotype and the dryness of stem cells, can promote the proliferation, differentiation, migration and anti-apoptosis of the stem cells and the tolerance of ischemia and hypoxia, and also can improve the anti-inflammatory effect, the immunoregulation effect and the paracrine effect of the stem cells. As discovered by research of Horie and the like, 2% hypoxia can promote the proliferation of mouse Neural Stem Cells (NSCs) compared with normoxic, and simultaneously does not influence the differentiation of the NSCs to astrocytes; in the review of the influence of the hypoxia microenvironment on the biological functions of the mesenchymal stem cells, such as cinnabar and the like, the mesenchymal stem cells can be inhibited from apoptosis and promoted to proliferate under the hypoxia environment with the oxygen integration number not less than 1%, but the promotion mechanism may have certain time dependence; ohnishi et al found that 139 and 49 genes were expressed in two types of cells, respectively, in bone marrow mesenchymal stem cells and monocytes cultured under 1% hypoxia condition. However, the role of extracellular matrix secreted by stem cells cultured in a hypoxic environment in diseases is rarely studied, and at present, no report on the use of extracellular matrix of human umbilical cord mesenchymal stem cells containing exosomes for repairing corneal epithelial cell injury is found.
Disclosure of Invention
The inventor creatively discovers that under the condition of hypoxia, the mesenchymal stem cells cultured in the culture medium with low serum concentration and containing polyvinyl alcohol can produce more factors and collagens which are beneficial to promoting the proliferation and damage repair of corneal epithelial cells, such as platelet-derived growth factor (PDGF) and type IV collagen, and the factors and the collagens are multiplied in the culture supernatant obtained by the invention and show that the factor and the collagen are obviously higher than the extracellular matrix composition obtained by culturing under the condition of normal oxygen content and serum content.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides a mesenchymal stem cell extracellular matrix containing exosome, and the preparation is culture supernatant produced by culturing human umbilical cord mesenchymal stem cells in a basal medium containing low-concentration serum under the condition of low oxygen content.
In most studies, mesenchymal stem cells are cultured under the normoxic condition (oxygen concentration is 21%), while the inventors found that the PDGF and type IV collagen in culture supernatant obtained by combining the culture of polyvinyl alcohol with lower serum concentration under the hypoxic condition are highly expressed, and an ELISA detection kit shows that the PDGF and type IV collagen positive expression rate is increased in a fold manner and has very significant difference (P is less than 0.01) compared with the normoxic 10% serogroup.
Particularly, the low oxygen content in the invention means that the oxygen content is 0.1-5%. In another aspect, the oxygen content is at least > 1%; in another aspect, the oxygen content may be any value between 1 to 5%, 1 to 4%, 1 to 3%, 1 to 2%. On the other hand, the oxygen content is preferably any value between 2 and 3%. During culture, when the hypoxia environment is simulated, a culture dish or a culture bottle is placed in a hypoxia device, and 95% nitrogen and 5% CO are introduced2To achieve the desired hypoxic environment, e.g., 1%. In contrast, an normoxic environment refers to 95% air + 5% CO2。
Particularly, the concentration of the serum in the serum-containing basic culture medium is 1-5%. In another aspect, the serum concentration is preferably > 3%; in another aspect, the serum concentration may be in the range of 3-4%, 3-5%; in another aspect, the serum concentration is 4% or 5%. It is to be noted that, in a hypoxic environment, the concentration of serum is particularly important for the growth and proliferation of mesenchymal stem cells, and at a concentration lower than 1%, good growth and proliferation of mesenchymal stem cells cannot be maintained, but higher than 5%, the expression of PDGF and type IV collagen in the obtained culture supernatant is reduced, and the higher the serum concentration is, the more unfavorable the high expression of PDGF and type IV collagen is. When the oxygen content of the system is maintained at 1-5%, the serum concentration in the growth medium is maintained within the range of 3-5%, and the PDGF and IV type collagen content is remarkably increased compared with that under the normoxic condition, which shows that the effect is only reflected between the lower serum concentration and the polyvinyl alcohol, but the synergistic effect does not exist between the high-concentration serum and the polyvinyl alcohol.
Particularly, the concentration of polyvinyl alcohol in the basic culture medium containing the serum is 1-3%.
PDGF plays an important role in tissue injury repair, while type IV collagen is an important component of the cornea, and in the test of promoting corneal epithelial cells, the culture supernatant obtained by culturing mesenchymal stem cells by adopting the culture medium under the condition of low oxygen concentration shows a more obvious role in promoting the proliferation of the corneal epithelial cells.
In particular, the basic medium in the invention is one of DMEM medium, low-sugar DMEM medium or DMEM/F12 medium. In particular, the basic medium is preferably DMEM/F12 medium.
The invention also provides a preparation method of the mesenchymal stem cell extracellular matrix, which comprises the following steps:
selecting P4-substituted mesenchymal stem cells with good proliferation capacity and growth state, inoculating the cells in a basic culture medium containing 1-5% of serum and 1-3% of polyvinyl alcohol, and adding 1-5% of O2、5％CO2Culturing at 37 deg.C for 12-48h, collecting culture medium supernatant, centrifuging, and filtering.
In the preparation method, the P4 generation mesenchymal stem cells can be obtained by using a conventional subculture method, and for example, the method can comprise the following steps:
collecting fresh umbilical cord tissue, cleaning, cutting into small pieces, removing umbilical artery, umbilical vein and epidermis, transferring into DMEM medium containing streptomycin and serum, and culturing at 37 deg.C with 5% CO2Culturing in saturated humidity chamber, changing liquid 1 time every 3 days, and adopting pancreas when the umbilical cord mesenchymal stem cells climb out more denselyEnzyme digestion and subculture.
In the above preparation method, the filtration treatment part may be performed by using an apparatus having filtration performance in the prior art, and a microporous membrane and an ultrafiltration tube are exemplified.
The invention also provides application of the mesenchymal stem cell extracellular matrix in preparing a preparation for promoting cell repair and regeneration. The cells referred to in the present invention are corneal epithelial cells.
The invention also provides a preparation with the function of repairing corneal epithelial cell injury, which contains the mesenchymal stem cell extracellular matrix. The extracellular matrix obtained under specific conditions contains more cytokines, such as PDGF and type IV collagen, so that the extracellular matrix can be prepared into preparations aiming at corneal injury, and particularly can be applied to repairing corneal epithelial cells. Such a preparation may be in the form of an eye-drop preparation, and when prepared into an eye-drop preparation, may further comprise various pharmaceutically acceptable adjuvants, and the preparation should theoretically further comprise various preservatives, cryoprotectants and stabilizers for maintaining the activity of cytokines at low temperatures. The various preservatives, cryoprotectants and stabilizers involved may generally be of the kind conventional in the art and may be selected according to the actual needs.
The invention has the beneficial effects that:
(1) according to the invention, the serum concentration is controlled to be kept in a lower range by simulating the hypoxia condition in vitro, and a certain amount of polyvinyl alcohol is added to culture the mesenchymal stem cells, so that PDGF and IV type collagen can be highly expressed.
(2) The extracellular matrix can also be prepared into a preparation for repairing corneal injury, and has more remarkable treatment effect compared with the traditional autologous serum and trophic factor eye drops.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example one, Single factor test
1.1 Effect of oxygen concentration
1.1.1 test methods
1.1.2 obtaining culture supernatants of human umbilical cord mesenchymal stem cells cultured in different oxygen concentrations: taking identified P4 generation human umbilical cord mesenchymal stem cells (hUCMSCs), adjusting cell concentration to 1 × 106Inoculating into a culture bottle containing DMEM/F12 medium containing 5% fetal calf serum and 2% polyvinyl alcohol, placing the culture bottle in a low oxygen box, and introducing mixed gas (95% N) at a flow rate of 1L/min2+5％CO2) To control the environment with different oxygen concentration, the culture bottle is placed under the condition of different oxygen concentration and 5% CO2Culturing at 37 deg.C for 48h, collecting culture medium supernatant, centrifuging, and filtering with microporous membrane.
1.1.3 Positive expression Rate assay for PDGF and type IV collagen: the culture supernatants obtained were tested for positive expression of PDGF and type IV collagen by ELISA kits and the results are shown in Table 1.
2 results
Table 1: comparison of Positive rates of PDGF and type IV collagen expression in culture supernatants of human umbilical cord mesenchymal stem cells in hypoxic and normoxic culture ((for example))
％)
Note:*p < 0.05, and normoxic group (21% O)2) And (6) comparing.
As can be seen from the above tables 1 and 2, compared with the normoxic group, in the culture supernatant obtained by culturing in the hypoxic environment, the expression positive rate of PDGF is higher, and when the oxygen content is 2-5%, the PDGF expression is significantly different from the normoxic group (P < 0.05); the positive expression rate and the highest expression rate of PDGF and IV type collagen are determined when the oxygen content is 2%, so that the serum concentration test is continued with the oxygen concentration of 2%.
1.2 Effect of serum concentration
Taking identified P4 generation human umbilical cord mesenchymal stem cells (hUCMSCs), adjusting cell concentration to 1 × 106Each of the flasks was filled with DMEM/F12 medium containing 1% by weight of serum, 2% by weight of serum, 3% by weight of serum, 4% by weight of serum, 5% by weight of serum, and 10% by weight of serum (the concentration of polyvinyl alcohol in each medium was controlled to 2%), and the flasks were placed in the same oxygen concentration (2% O)2、95％N2、 5％CO2) Culturing at 37 deg.C for 48h, collecting culture medium supernatant, centrifuging, and filtering with microporous membrane. The positive expression rates of PDGF and type IV collagen in the collected culture supernatants were determined using the kit, and the results are shown in Table 2.
Table 2: comparison of Positive rates of PDGF and type IV collagen expression in culture supernatants obtained by culture at different serum concentrations (for example:)
％)
Note: p < 0.05, P < 0.01 compared to the 10% serogroup.
The results show that at 2% O2Under the hypoxic environment, the positive expression rates of PDGF and IV type collagen in culture supernatant are gradually improved along with the increase of serum concentration within the range of 1-5%, but when the serum concentration reaches 10%, the positive expression rates of PDGF and IV type collagen are obviously reduced, and the result shows that under the hypoxic environment, the expression of PDGF and IV type collagen can be effectively promoted by polyvinyl alcohol and serum with lower concentration, and the effect is improved along with the increase of serum concentration within the range of 3-5% of serum concentration, but the effect does not exist under the condition of higher serum concentration (10%). When the serum concentration is 3-5%, the PDGF and IV type collagen expression is in the same phase with 10% of serumThere was a very significant difference from the results obtained in the low oxygen environment, where the supernatants obtained from 5% FBS cultures contained the most PDGF and type IV collagen, and 5% serum concentrations, 2% O were selected2Proceed to the next test.
1.3 Effect of containing and not containing polyvinyl alcohol
Taking identified P4 generation human umbilical cord mesenchymal stem cells (hUCMSCs), adjusting cell concentration to 1 × 106Separately, the culture flasks were placed in DMEM/F12 medium containing 5% serum, 2% polyvinyl alcohol and 5% serum, and the flasks were placed in the same oxygen concentration (2% O)2、95％N2、5％CO2) Culturing at 37 deg.C for 48h, collecting culture medium supernatant, centrifuging, and filtering with microporous membrane. The positive expression rates of PDGF and type IV collagen in the collected culture supernatants were determined using the kit, and the results are shown in Table 3.
Table 3: comparison of Positive rates of PDGF and type IV collagen expression in culture supernatants obtained by culture at different serum concentrations (for example:)
％)
Note: p < 0.05, compared to 5% serogroup.
The results show that the culture with the addition of the polyvinyl alcohol can obviously improve the expression of the type IV collagen, and compared with the culture without the polyvinyl alcohol, the culture with the addition of the polyvinyl alcohol has very obvious difference.
In conclusion, in the process of culturing the mesenchymal stem cells, on the basis of a single-factor test, the optimal conditions of culture are determined as follows: oxygen concentration 2% O2(volume fraction), the serum concentration of the medium is 5%, and the polyvinyl alcohol is preferably contained at a concentration of 2%. Under the condition, the PDGF positive expression rate in the culture supernatant reaches 62.35%, and the collagen type IV positive expression rate reaches 51.24%. The result shows that the mesenchymal stem cells can be high by adopting low-concentration serum and polyvinyl alcohol to culture in the hypoxia environmentPDGF and type IV collagen are expressed. The obtained culture supernatant was subjected to a test for promoting proliferation of corneal epithelial cells.
Test for promoting proliferation of corneal epithelial cells
S1, primary isolation and subculture amplification culture of human umbilical cord mesenchymal stem cells: collecting fresh umbilical cord tissue, cleaning, cutting into small pieces, removing umbilical artery, umbilical vein and epidermis, transferring into DMEM medium containing streptomycin and serum, and culturing at 37 deg.C with 5% CO2Culturing in a saturated humidity box, changing the liquid for 1 time every 3 days, and digesting by pancreatin when the umbilical cord mesenchymal stem cells climb out more densely, and carrying out subculture;
s2, obtaining culture supernatant of human umbilical cord mesenchymal stem cells: taking identified P4 generation human umbilical cord mesenchymal stem cells (hUCMSCs), adjusting cell concentration to 1 × 106Inoculating into a culture bottle containing DMEM/F12 medium containing 5% fetal calf serum and 2% polyvinyl alcohol, placing the culture bottle in a low oxygen box, and introducing mixed gas (95% N) at a flow rate of 1L/min2+5％CO2) Controlling the oxygen concentration in the hypoxia chamber to be 2%, culturing at the constant temperature of 37 ℃ for 48h, collecting culture medium supernatant, centrifuging, and filtering with a microporous filter membrane to obtain the product.
Corneal epithelial cells were seeded in a 96-well plate at a density of 1000 cells/well, and the culture supernatants obtained above were added for culture, and proliferation of corneal epithelial cells was measured by CCK-8 reagent at 12 hours, 24 hours, and 48 hours, and the results are shown in Table 4.
Table 4: the proliferation of corneal epithelial cells (OD value,
)
corneal epithelial injury repair test
Corneal epithelial cells were cultured at 2X 105Inoculating the cells/well into a 96-well plate, adding DMEM medium containing 10% fetal bovine serum to culture, when the cell fusion degree reaches 100%,washing with DPBS solution for 2 times, scratching and molding with 10 μ L gun head every 1cm, washing with DPBS solution, adding the culture supernatant at 37 deg.C and 5% CO2Culturing under the condition of (1), observing by an inverted microscope at 12h, 24 h and 48h, photographing, and performing statistical analysis.
Table 5: test results of corneal epithelial cell injury repair
The results in tables 4 and 5 show that the culture supernatants prepared by the method of the invention have significant promotion effect on the proliferation of corneal epithelial cells; the wound surface of the damaged corneal epithelial cells is gradually reduced, and the excellent function of promoting the repair of the corneal epithelial cell damage is shown.
Finally, it should be noted that the above embodiments are intended to illustrate the technical solutions of the present invention and not to limit the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. An extracellular matrix of mesenchymal stem cells comprising exosomes, characterized in that the preparation is a culture supernatant produced by culturing human umbilical cord mesenchymal stem cells in a basal medium containing low concentration of serum under low oxygen content conditions.
2. The extracellular matrix of mesenchymal stem cells according to claim 1, wherein the low oxygen content is 0.1-5% oxygen content.
3. The mesenchymal stem cell extracellular matrix according to claim 1 or 2, wherein the serum concentration in the serum-containing basal medium is 1-5%.
4. The mesenchymal stem cell extracellular matrix of claim 3, wherein the serum-containing basal medium further comprises polyvinyl alcohol.
5. The extracellular matrix of mesenchymal stem cells according to claim 4, wherein the concentration of polyvinyl alcohol in the serum-containing basal medium is 1-3%.
6. The extracellular matrix of mesenchymal stem cells according to any one of claims 1 to 5, wherein the basal medium is one of DMEM medium, low-sugar DMEM medium or DMEM/F12 medium.
7. The method for preparing extracellular matrix of mesenchymal stem cell according to any one of claims 1 to 6, comprising the steps of:
selecting P4-substituted mesenchymal stem cells with good proliferation capacity and growth state, inoculating the cells in a basic culture medium containing 1-5% of serum and 1-3% of polyvinyl alcohol, and adding 1-5% of O2、5％CO2Culturing at 37 deg.C for 12-48h, collecting culture medium supernatant, centrifuging, and filtering.
8. Use of the extracellular matrix of mesenchymal stem cells according to any one of claims 1 to 6 in the preparation of a preparation for promoting cell repair and regeneration.
9. Use according to claim 8, wherein the cells are corneal epithelial cells.
10. A preparation having a function of repairing corneal epithelial cell damage, comprising the mesenchymal stem cell extracellular matrix according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210075818.4A CN114350603B (en) | 2022-01-23 | 2022-01-23 | Mesenchymal stem cell extracellular matrix containing exosome, preparation method thereof and application thereof in cell repair |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210075818.4A CN114350603B (en) | 2022-01-23 | 2022-01-23 | Mesenchymal stem cell extracellular matrix containing exosome, preparation method thereof and application thereof in cell repair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114350603A true CN114350603A (en) | 2022-04-15 |
| CN114350603B CN114350603B (en) | 2022-08-23 |
Family
ID=81091702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210075818.4A Active CN114350603B (en) | 2022-01-23 | 2022-01-23 | Mesenchymal stem cell extracellular matrix containing exosome, preparation method thereof and application thereof in cell repair |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114350603B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115029308A (en) * | 2022-07-30 | 2022-09-09 | 广州高华生物科技有限公司 | Stem cell exosome preparation and preparation method and application thereof |
| CN115125198A (en) * | 2022-07-11 | 2022-09-30 | 湖北沃德利派生物科技有限公司 | Human umbilical cord mesenchymal stem cell exosome and preparation method and application thereof |
| CN115491352A (en) * | 2022-11-16 | 2022-12-20 | 广东先康达生物科技有限公司 | Culture solution for promoting secretion of stem cell exosomes, preparation of exosomes and application of exosomes |
| CN117547554A (en) * | 2024-01-12 | 2024-02-13 | 山东康根源生物集团有限公司 | Mesenchymal stem cell repair preparation and preparation method thereof |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525594A (en) * | 2009-04-17 | 2009-09-09 | 中国医学科学院血液学研究所 | Complete medium with low serum concentration for cultivating mesenchymal stem cells and method for cultivating mesenchymal stem cells using same |
| WO2015034212A1 (en) * | 2013-09-05 | 2015-03-12 | Medipost Co., Ltd. | Method for culturing mesenchymal stem cells according to cell size |
| CN106701670A (en) * | 2015-08-05 | 2017-05-24 | 朱轶 | Methods for enhancing bioactive factor secretion capacity of mesenchymal stem cells and extracting active factors in culture solution |
| CN108251359A (en) * | 2017-12-20 | 2018-07-06 | 上海华新生物高技术有限公司 | A kind of mesenchymal stem cell serum-free culture medium and cultural method |
| CN108823159A (en) * | 2018-07-13 | 2018-11-16 | 李璇 | The influence for the excretion body that PDGF-BB discharges mescenchymal stem cell |
| CN110157666A (en) * | 2019-05-27 | 2019-08-23 | 佛山市精准吉因健康管理咨询有限公司 | Umbilical cord mesenchymal stem cells MSCs and its cultural method and application |
| CN110433137A (en) * | 2019-09-04 | 2019-11-12 | 北京中广天一生物科技有限公司 | A kind of application of the ossium mesenchyma stem cell paracrine factor in eye drops |
| CN110564680A (en) * | 2019-08-27 | 2019-12-13 | 西安艾尔菲生物科技有限公司 | Human umbilical cord mesenchymal stem cell serum-free culture medium, preparation method thereof and method for obtaining human umbilical cord mesenchymal stem cell serum-free culture medium |
| CN110923196A (en) * | 2019-12-03 | 2020-03-27 | 广州赛莱拉干细胞科技股份有限公司 | Serum-free medium, preparation method thereof and mesenchymal stem cell culture method |
| CN111565732A (en) * | 2018-01-12 | 2020-08-21 | 国立大学法人大阪大学 | Agent for promoting normal differentiation-maturation of stratified squamous epithelial cell, agent for treating epithelial disease, and method for promoting normal differentiation-maturation of stratified squamous epithelial cell |
| US10758571B1 (en) * | 2019-04-09 | 2020-09-01 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
| CN113564111A (en) * | 2021-08-23 | 2021-10-29 | 上海太安堂生物医学有限公司 | Method for culturing umbilical cord-derived mesenchymal stem cells under low oxygen |
-
2022
- 2022-01-23 CN CN202210075818.4A patent/CN114350603B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525594A (en) * | 2009-04-17 | 2009-09-09 | 中国医学科学院血液学研究所 | Complete medium with low serum concentration for cultivating mesenchymal stem cells and method for cultivating mesenchymal stem cells using same |
| WO2015034212A1 (en) * | 2013-09-05 | 2015-03-12 | Medipost Co., Ltd. | Method for culturing mesenchymal stem cells according to cell size |
| CN106701670A (en) * | 2015-08-05 | 2017-05-24 | 朱轶 | Methods for enhancing bioactive factor secretion capacity of mesenchymal stem cells and extracting active factors in culture solution |
| CN108251359A (en) * | 2017-12-20 | 2018-07-06 | 上海华新生物高技术有限公司 | A kind of mesenchymal stem cell serum-free culture medium and cultural method |
| CN111565732A (en) * | 2018-01-12 | 2020-08-21 | 国立大学法人大阪大学 | Agent for promoting normal differentiation-maturation of stratified squamous epithelial cell, agent for treating epithelial disease, and method for promoting normal differentiation-maturation of stratified squamous epithelial cell |
| CN108823159A (en) * | 2018-07-13 | 2018-11-16 | 李璇 | The influence for the excretion body that PDGF-BB discharges mescenchymal stem cell |
| US10758571B1 (en) * | 2019-04-09 | 2020-09-01 | Combangio, Inc. | Processes for making and using a mesenchymal stem cell derived secretome |
| CN110157666A (en) * | 2019-05-27 | 2019-08-23 | 佛山市精准吉因健康管理咨询有限公司 | Umbilical cord mesenchymal stem cells MSCs and its cultural method and application |
| CN110564680A (en) * | 2019-08-27 | 2019-12-13 | 西安艾尔菲生物科技有限公司 | Human umbilical cord mesenchymal stem cell serum-free culture medium, preparation method thereof and method for obtaining human umbilical cord mesenchymal stem cell serum-free culture medium |
| CN110433137A (en) * | 2019-09-04 | 2019-11-12 | 北京中广天一生物科技有限公司 | A kind of application of the ossium mesenchyma stem cell paracrine factor in eye drops |
| CN110923196A (en) * | 2019-12-03 | 2020-03-27 | 广州赛莱拉干细胞科技股份有限公司 | Serum-free medium, preparation method thereof and mesenchymal stem cell culture method |
| CN113564111A (en) * | 2021-08-23 | 2021-10-29 | 上海太安堂生物医学有限公司 | Method for culturing umbilical cord-derived mesenchymal stem cells under low oxygen |
Non-Patent Citations (5)
| Title |
|---|
| BINDER BY 等: "Reduced serum and hypoxic culture conditions enhance the osteogenic potential of human mesenchymal stem cells", 《STEM CELL REV REP》 * |
| DETAMORE MS 等: "Human umbilical cord mesenchymal stromal cells in regenerative medicine", 《STEM CELL RES THER》 * |
| 付长秀 等: "间充质干细胞外泌体在眼部疾病中的研究进展", 《中国免疫学杂志》 * |
| 刘保池 等: "《细胞治疗临床研究》", 30 November 2019, 上海：复旦大学出版社 * |
| 张美荣等: "人脐带间充质干细胞体外分泌的伤口愈合相关因子", 《中国组织工程研究与临床康复》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115125198A (en) * | 2022-07-11 | 2022-09-30 | 湖北沃德利派生物科技有限公司 | Human umbilical cord mesenchymal stem cell exosome and preparation method and application thereof |
| CN115125198B (en) * | 2022-07-11 | 2024-01-26 | 湖北沃德利派生物科技有限公司 | Human umbilical cord mesenchymal stem cell exosome and preparation method and application thereof |
| CN115029308A (en) * | 2022-07-30 | 2022-09-09 | 广州高华生物科技有限公司 | Stem cell exosome preparation and preparation method and application thereof |
| CN115491352A (en) * | 2022-11-16 | 2022-12-20 | 广东先康达生物科技有限公司 | Culture solution for promoting secretion of stem cell exosomes, preparation of exosomes and application of exosomes |
| CN117547554A (en) * | 2024-01-12 | 2024-02-13 | 山东康根源生物集团有限公司 | Mesenchymal stem cell repair preparation and preparation method thereof |
| CN117547554B (en) * | 2024-01-12 | 2024-05-14 | 山东康根源生物集团有限公司 | Mesenchymal stem cell repair preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114350603B (en) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114350603B (en) | Mesenchymal stem cell extracellular matrix containing exosome, preparation method thereof and application thereof in cell repair | |
| US20110217385A1 (en) | Method for extracting mesenchymal stem cell from human or animal embryo and for extracting the secretion product thereof | |
| CN108823156A (en) | For the clinical grade human umbilical cord mesenchymal stem cells composite factor of reparation and the preparation method of freeze-dried powder | |
| CN110812318B (en) | Method for preparing optimized fibroblast extract for cosmetic raw material | |
| CN112725270B (en) | Human-derived bone marrow mesenchymal stem cell induction culture medium and induction method | |
| CN105663168A (en) | Cell preparation for repairing ovarian functions | |
| CN109929800A (en) | A kind of acquisition of stem cell secretion factor and purification process | |
| CN106924285A (en) | A kind of placenta mesenchyma stem cell parenteral solution and its preparation method and application | |
| CN110507597A (en) | A kind of composition and preparation method thereof, application | |
| CN113943699B (en) | Umbilical cord mesenchymal stem cell induction liquid for resisting high sugar injury, method and application | |
| CN116083355B (en) | Method for improving therapeutic capacity of umbilical mesenchymal stem cells | |
| CN106282101A (en) | A kind of promote the human amnion mesenchymal stem cell method to Chondrocyte Differentiation and application | |
| Singh et al. | Current approaches for the regeneration and reconstruction of ocular surface in dry eye | |
| CN111617105A (en) | Preparation method of adipose-derived stem cell multi-cell active factor freeze-dried powder | |
| CN109777771A (en) | The serum free medium and its application method of primary umbilical cord mesenchymal stem cells | |
| CN114574435A (en) | Composition for inducing umbilical cord mesenchymal stem cells to secrete cytokines and application thereof | |
| EP3957717B1 (en) | Rapid and efficient method for expanding human mesenchymal stem cells in vitro and application thereof | |
| CN113652398A (en) | Method and compound for enhancing mucosa repair effect of mesenchymal stem cell exosome | |
| CN112708595A (en) | Induction medium and induction method for SD rat-derived mesenchymal stem cells | |
| CN102641296A (en) | Preparation for inhibiting immunity and treating graft-versus-host diseases (GVHD) and preparation method of preparation | |
| CN113583938A (en) | Method for forming islet-like structure by islet cells differentiated by in vitro induced stem cells | |
| CN104894088A (en) | Digestive enzyme composition and application thereof, and isolated culture method of umbilical epithelial cells | |
| CN116836920B (en) | Serum-free culture medium and method for preparing mesenchymal stem cells by using same | |
| CN110478369A (en) | A kind of composite dry cell bioagent | |
| CN106282089B (en) | A kind of efficient amplification cultivating system of non-human primate endothelial progenitor cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220803 Address after: Room 501, floor 5, building 14, No. 615, Lianhe Road, Chedun Town, Songjiang District, Shanghai 201600 Applicant after: Shanghai lanweisaier Biotechnology Co.,Ltd. Address before: 510000 room c421, No. 66, Honghuagang West Street, cen village, Tianhe District, Guangzhou City, Guangdong Province Applicant before: Guangzhou Yuankang Biomedical Technology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |